Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022

前列腺癌 医学 投票 协商一致会议 肿瘤科 德尔菲法 前列腺 疾病 内科学 前列腺癌的治疗 癌症 妇科 家庭医学 政治学 法学 统计 政治 数学
作者
Silke Gillessen,Alberto Bossi,Ian D. Davis,Johann de Bono,Karim Fizazi,Nicholas D. James,Nicolas Mottet,Neal D. Shore,Eric J. Small,Matthew Smith,Christopher J. Sweeney,Bertrand Tombal,Emmanuel S. Antonarakis,Ana Aparicio,Andrew J. Armstrong,Gerhardt Attard,Tomasz M. Beer,Himisha Beltran,Anders Bjartell,Pierre Blanchard,Alberto Briganti,Robert G. Bristow,Muhammad Bulbul,Orazio Caffo,Daniel Castellano,Elena Castro,Heather H. Cheng,Kim N.,Simon Chowdhury,Caroline Clarke,Noel W. Clarke,Gedske Daugaard,Maria De Santis,Ignacio Durán,Ros Eeles,Eleni Efstathiou,Jason A. Efstathiou,Onyeanunam Ngozi Ekeke,Christopher P. Evans,Stefano Fanti,Felix Y. Feng,Valérie Fonteyne,Nicola Fossati,Mark Frydenberg,Daniel J. George,Martin Gleave,G. Gravis,Susan Halabi,Daniel Heinrich,Ken Herrmann,Celestia S. Higano,Michael S. Hofman,Lisa G. Horvath,Maha Hussain,Barbara Alicja Jereczek‐Fossa,Robert J. Jones,Ravindran Kanesvaran,Pirkko-Liisa Kellokumpu-Lehtinen,Raja B. Khauli,Laurence Klotz,Gero Kramer,Raya Leibowitz,Christopher J. Logothetis,Brandon A. Mahal,Fernando C. Maluf,Joaquı́n Mateo,David Matheson,Niven Mehra,Axel S. Merseburger,Alicia K. Morgans,Michael J. Morris,Hind Mrabti,Deborah Mukherji,Declan G. Murphy,Vedang Murthy,Paul L. Nguyen,William Oh,Piet Ost,Joe M. O’Sullivan,Anwar R. Padhani,Carmel Pezaro,Darren M.C. Poon,Colin C. Pritchard,Danny Rabah,Dana E. Rathkopf,Robert E. Reiter,Mark A. Rubin,Charles J. Ryan,Fred Saad,Juan Pablo Sade,Oliver Sartor,Howard I. Scher,Nima Sharifi,Iwona Skoneczna,Howard R. Soule,Daniel E. Spratt,Sandy Srinivas,Cora N. Sternberg,Thomas Steuber,Hiroyoshi Suzuki,Matthew R. Sydes,Mary‐Ellen Taplin,Derya Tilki,Levent Türkeri,Fabio Turco,Hiroji Uemura,Hirotsugu Uemura,Yüksel Ürün,Claire Vale,Inge M. van Oort,Neha Vapiwala,Jochen Walz,Kosj Yamoah,Dingwei Ye,Evan Y. Yu,A. Zapatero,Thomas Zilli,Aurelius Omlin
出处
期刊:European Urology [Elsevier BV]
卷期号:83 (3): 267-293 被引量:51
标识
DOI:10.1016/j.eururo.2022.11.002
摘要

Innovations in imaging and molecular characterisation and the evolution of new therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue to lack high-level evidence on a variety of clinical topics that greatly impact daily practice. To supplement evidence-based guidelines, the 2022 Advanced Prostate Cancer Consensus Conference (APCCC 2022) surveyed experts about key dilemmas in clinical management.To present consensus voting results for select questions from APCCC 2022.Before the conference, a panel of 117 international prostate cancer experts used a modified Delphi process to develop 198 multiple-choice consensus questions on (1) intermediate- and high-risk and locally advanced prostate cancer, (2) biochemical recurrence after local treatment, (3) side effects from hormonal therapies, (4) metastatic hormone-sensitive prostate cancer, (5) nonmetastatic castration-resistant prostate cancer, (6) metastatic castration-resistant prostate cancer, and (7) oligometastatic and oligoprogressive prostate cancer. Before the conference, these questions were administered via a web-based survey to the 105 physician panel members ("panellists") who directly engage in prostate cancer treatment decision-making. Herein, we present results for the 82 questions on topics 1-3.Consensus was defined as ≥75% agreement, with strong consensus defined as ≥90% agreement.The voting results reveal varying degrees of consensus, as is discussed in this article and shown in the detailed results in the Supplementary material. The findings reflect the opinions of an international panel of experts and did not incorporate a formal literature review and meta-analysis.These voting results by a panel of international experts in advanced prostate cancer can help physicians and patients navigate controversial areas of clinical management for which high-level evidence is scant or conflicting. The findings can also help funders and policymakers prioritise areas for future research. Diagnostic and treatment decisions should always be individualised based on patient and cancer characteristics (disease extent and location, treatment history, comorbidities, and patient preferences) and should incorporate current and emerging clinical evidence, therapeutic guidelines, and logistic and economic factors. Enrolment in clinical trials is always strongly encouraged. Importantly, APCCC 2022 once again identified important gaps (areas of nonconsensus) that merit evaluation in specifically designed trials.The Advanced Prostate Cancer Consensus Conference (APCCC) provides a forum to discuss and debate current diagnostic and treatment options for patients with advanced prostate cancer. The conference aims to share the knowledge of international experts in prostate cancer with health care providers and patients worldwide. At each APCCC, a panel of physician experts vote in response to multiple-choice questions about their clinical opinions and approaches to managing advanced prostate cancer. This report presents voting results for the subset of questions pertaining to intermediate- and high-risk and locally advanced prostate cancer, biochemical relapse after definitive treatment, advanced (next-generation) imaging, and management of side effects caused by hormonal therapies. The results provide a practical guide to help clinicians and patients discuss treatment options as part of shared multidisciplinary decision-making. The findings may be especially useful when there is little or no high-level evidence to guide treatment decisions.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
英姑的应助被笑点低薯片采纳,获得10
刚刚
夏弱完成签到,获得积分10
1秒前
高级的百香果完成签到,获得积分10
2秒前
April完成签到,获得积分10
2秒前
JamesPei的应助被Alexlovar采纳,获得30
3秒前
3秒前
青山白鸟完成签到 ,获得积分10
4秒前
4秒前
YDB发布了新的文献求助10
4秒前
5秒前
5秒前
充电宝的应助被三十六采纳,获得10
5秒前
D_DAY发布了新的文献求助10
5秒前
科研通AI2S的应助被只因采纳,获得10
6秒前
7秒前
fiveby完成签到 ,获得积分10
7秒前
jean发布了新的文献求助10
8秒前
彭于晏的应助被思恩Shen采纳,获得10
8秒前
Lars发布了新的文献求助10
8秒前
fanfan完成签到,获得积分10
9秒前
李妍发布了新的文献求助80
9秒前
小古完成签到,获得积分10
10秒前
PEACE发布了新的文献求助10
11秒前
11秒前
12秒前
12秒前
14秒前
fishss完成签到,获得积分0
15秒前
MADAO发布了新的文献求助30
15秒前
Nidhogg完成签到,获得积分20
16秒前
852的应助被俭朴钢铁侠采纳,获得10
16秒前
那地方完成签到,获得积分0
16秒前
小马甲的应助被等风归采纳,获得10
16秒前
小蜜蜂完成签到,获得积分10
16秒前
在水一方的应助被喝口可乐采纳,获得30
16秒前
LW3366发布了新的文献求助10
17秒前
马亚斌发布了新的文献求助10
17秒前
秋风的应助被芒果彩虹猪采纳,获得20
18秒前
GPTea的应助被jean采纳,获得20
18秒前
applennad完成签到,获得积分10
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181839
求助须知:如何正确求助?哪些是违规求助? 9571584
关于积分的说明 21818707
捐赠科研通 7778124
什么是DOI,文献DOI怎么找? 3433524
关于科研通互助平台的介绍 2557710
邀请新用户注册赠送积分活动 2479621